News | February 23, 2024
AstraZeneca completes acquisition of Gracell
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Furthering cell therapy ambition across oncology and autoimmune diseases
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Subscribe To Our Newsletter & Stay Updated
